作者: Weilian Yang , Rolf F. Barth , Joan H. Rotaru , Melvin L. Moeschberger , Darrel D. Joel
关键词: Chemistry 、 Mannitol 、 Nuclear medicine 、 Endocrinology 、 Internal medicine 、 Blood–brain barrier 、 Radiation therapy 、 Central nervous system disease 、 Pharmacokinetics 、 Biodistribution 、 Glioma 、 Boron
摘要: Boronophenylalanine (BPA) has been used for boron neutron capture therapy (BNCT) of brain tumors in both experimental animals and humans. The purpose the present study was to determine if efficacy BNCT could be enhanced by means intracarotid (i.c.) injection BPA with or without blood-brain barrier disruption (BBB-D) irradiation using a rat tumor model. For biodistribution studies, F98 glioma cells were implanted stereotactically into brains Fischer rats, and12 days later BBB-D carried out i.c. infusion 25% mannitol (1.373 mOsmol/ml), followed immediately administration 300, 500 800 mg BPA/kg body weight (b.w.). At dose fourfold increase concentration (94.5 μg/g) seen at 2.5 hours after BBB-D, compared 20.8 μg/g i.v. injected animals. best composite normal tissue ratios observed which time tumor: blood (T: Bl) ratio was10.9, Br) 7.5, 3.2 5.0 respectively rats. In contrast, that had received T: Bl Br 8.5 5.9, respectively, 42.7μg/g. experiments, initiated 14 intracerebral implantation cells, mg/kg b.w. administered irradiated hourslater Brookhaven Medical Research Reactor collimated beam thermal neutrons delivered head. mean survival untreated control rats 24 ± 3 days, 30 2 controls, 37 those receiving BPA, 52 15 95 BNCT. latter group 246% life span (ILS) controls 124% ILS These data are ever obtained model suggest may useful as